Trials / Completed
CompletedNCT03538028
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Incyte Biosciences International Sàrl · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
Conditions
- Cervical Cancer
- Microsatellite Instability (MSI)-High Endometrial Cancer
- Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])
- Esophageal Cancer
- Hepatocellular Carcinoma
- Melanoma (Uveal Melanoma Excluded)
- Merkel Cell Carcinoma
- Mesothelioma
- MSI-high Colorectal Cancer
- Non-small Cell Lung Cancer (NSCLC)
- Ovarian Cancer
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Small Cell Lung Cancer (SCLC)
- Renal Cell Carcinoma (RCC)
- Triple-negative Breast Cancer
- Urothelial Carcinoma
- Diffuse Large B-cell Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | INCAGN02385 | INCAGN02385 administered as an intravenous infusion over 30 minutes. |
Timeline
- Start date
- 2018-06-18
- Primary completion
- 2020-10-07
- Completion
- 2020-10-07
- First posted
- 2018-05-25
- Last updated
- 2020-10-30
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03538028. Inclusion in this directory is not an endorsement.